Phase II trial of the cannabinoid compounds, GWP 42003 and GWP 42004, in patients with metabolic disorders.
Latest Information Update: 01 Oct 2012
Price :
$35 *
At a glance
- Drugs Cannabidiol (Primary) ; Cannabidiol/tetrahydrocannabivarin-9 (Primary) ; Tetrahydrocannabivarin 9 (Primary)
- Indications Metabolic syndrome; Type 2 diabetes mellitus
- Focus Therapeutic Use
- 01 Oct 2012 New trial record